Low-grade serous ovarian cancer (LGSC), accounts for just 5% to 10% of all epithelial ovarian cancers, but its distinct biology makes it especially challenging to treat. While the origin of this ...

CAR-T therapy targeting TM4SF1 in aggressive bladder cancer (HV) histologic variant , offering hope for treatment-resistant ...

Non-invasive epithelial tumors of the ovary that show abnormal cell growth but lack the capacity to invade surrounding ...

An interdisciplinary study uncovers how benign borderline ovarian tumors develop into invasive low-grade serous carcinoma, ...

Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression, Cancer Cell, June 2025 DOI: (25)00253-3 ...

A diagnosis of 4 stage ovarian cancer can be devastating. However, advances in medical science are helping patients and offering them hope ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

A new technique lets researchers make many more of the particles much faster, using consistent practices that meet safety ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across ...